Show simple item record

Real-life effect of a microcrystalline tyrosine adjuvanted mite immunotherapy in patients with allergic rhinitis

dc.contributor.authorRoger, A
dc.contributor.authorMalet, A
dc.contributor.authorMoreno, V
dc.contributor.authorParra Arrondo, Antonio 
dc.contributor.authorGutierrez, D
dc.contributor.authorLleonart, R
dc.contributor.authorMoreno, F
dc.contributor.authorValero, A
dc.contributor.authorNavarro, B
dc.contributor.authorHinojosa, B
dc.contributor.authorJusticia, JL
dc.date.accessioned2022-04-12T11:37:21Z
dc.date.available2022-04-12T11:37:21Z
dc.date.issued2020
dc.identifier.issn1750-743X
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/31910695es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16454
dc.description.abstractAim: Evaluate the effectiveness and safety of immunotherapy with Acarovac Plus((R)) in a 1-year prospective multicentered real-life study. Methods: A total of 118 adults with allergic rhinitis sensitized to Dermatophagoides received subcutaneous immunotherapy with Acarovac Plus. Treatment outcomes were evaluated at baseline, 6 months and 1 year after treatment initiation. Primary end point was the evolution of the combined symptom and medication score. Secondary end points included other effectiveness outcomes and measurement of product tolerability. Results: Acarovac Plus induced significant improvements in primary and secondary end points after 6 months compared with baseline. These differences persisted after 1 year of treatment (p < 0.001; baseline vs 1 year): combined symptom and medication score (1.60 vs 0.79). No serious adverse events were recorded. Conclusion: Acarovac Plus for 1 year was effective and well tolerated in a real-life setting.en
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.meshInjections*
dc.subject.meshAdult*
dc.subject.meshMiddle Aged*
dc.subject.meshAntigens*
dc.subject.meshAdolescent*
dc.subject.meshPyroglyphidae*
dc.subject.meshAnimals*
dc.subject.meshNovobiocin*
dc.subject.meshRhinitis*
dc.subject.meshTyrosine*
dc.subject.meshHumans*
dc.subject.meshTreatment Outcome*
dc.subject.meshYoung Adult*
dc.subject.meshProspective Studies*
dc.subject.meshAged*
dc.titleReal-life effect of a microcrystalline tyrosine adjuvanted mite immunotherapy in patients with allergic rhinitisen
dc.typeJournal Articlees
dc.authorsophosRoger, A Malet, A Moreno, V Parra, A Gutierrez, D Lleonart, R Moreno, F Valero, A Navarro, B Hinojosa, B Justicia, JL
dc.identifier.doi10.2217/imt-2019-0205
dc.identifier.pmid31910695
dc.identifier.sophos38857
dc.issue.number1es
dc.journal.titleImmunotherapyes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña::Alergoloxíaes
dc.page.initial53es
dc.page.final62es
dc.rights.accessRightsopenAccess
dc.subject.decsresultado del tratamiento *
dc.subject.decsanimales *
dc.subject.decsestudios prospectivos *
dc.subject.decsmediana edad *
dc.subject.decsnovobiocina *
dc.subject.decsinyecciones *
dc.subject.decsadulto *
dc.subject.decsantígenos*
dc.subject.decsanciano*
dc.subject.decsadulto joven*
dc.subject.decshumanos*
dc.subject.decstirosina*
dc.subject.decsPyroglyphidae*
dc.subject.decsrinitis*
dc.subject.decsadolescente*
dc.subject.keywordCHUACes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number12es


Files in this item

Download/Open
Name:
38857-799.pdf
Size:
875.1Kb
Format:
PDF
Description:
Immunotherapy. 2020 Jan;12(1):53-62

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International